Clinical trial • Oncology|Gastroenterology
bevacizumab for Metastatic colorectal cancer|Colorectal cancer
Clinical trial of bevacizumab for Metastatic colorectal cancer|Colorectal cancer. 48 participants.
Overview
- Trial Therapeutic Area
- Oncology|Gastroenterology
- Trial Disease
- Metastatic colorectal cancer|Colorectal cancer
- Drug Modality
- Small molecule|Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 01-07-2024
- First CTIS Authorization Date
- 02-08-2024
Trial design
Clinical trial across 2 sites in France.
- Target Sample Size
- 48
Eligibility
Recruits 48 isVulnerablePopulationSelected: false; no vulnerable population selected; consent/assent handling not specified..
- Vulnerable Population
- isVulnerablePopulationSelected: false; no vulnerable population selected; consent/assent handling not specified.
Recruitment
- Planned Sample Size
- 48
- Recruitment Window Months
- 84
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 48
France
- Earliest CTIS Part Ii Submission Date
- 27-06-2024
- Latest Decision Or Authorization Date
- 02-08-2024
- Processing Time Days
- 36
- Number Of Sites
- 2
- Number Of Participants
- 48
Sites
- Site Name
- Centr Georges Francois Leclerc
- Department Name
- Oncology
- Principal Investigator Name
- Jean-David Fumet
- Principal Investigator Email
- jdfumet@cgfl.fr
- Contact Person Name
- Jean-David Fumet
- Contact Person Email
- jdfumet@cgfl.fr
- Site Name
- Centre Hospitalier William Morey
- Department Name
- Oncology
- Principal Investigator Name
- Axelle Boudrant
- Principal Investigator Email
- axelle.boudrant@ch-chalon71.fr
- Contact Person Name
- Axelle Boudrant
- Contact Person Email
- axelle.boudrant@ch-chalon71.fr
Sponsor
Primary sponsor
- Full Name
- Centr Georges Francois Leclerc
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- FOLFIRINOX3
- Modality
- Small molecule
- Investigational Product Name
- Bevacizumab
- Active Substance
- bevacizumab
- Modality
- Monoclonal antibody
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- ALECTINIB for Metastatic colorectal cancer|Colorectal cancer
- Girentuximab (labelled with Zirconium-89) for Gastroenteropancreatic neuroendocrine neoplasms|Hepatocellular carcinoma|Biliary tract cancer
- DOSTARLIMAB for Resectable colon cancer (pMMR/MSS)
- D,L-LYSINE ACETYLSALICYLATE for Metastatic colorectal cancer|Chemo-resistant metastatic colorectal cancer
- BEVACIZUMAB for Advanced hepatocellular carcinoma|Liver transplant recipient